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The polyisoprenoid compound undecaprenyl phosphate is
required for biosynthesis of cell wall peptidoglycans in Gram-
positive bacteria, including pathogenic Enterococcus, Strep-
tococcus, and Staphylococcus spp. In these organisms, the
mevalonate pathway is used to produce the precursor isopre-
noid, isopentenyl 5-diphosphate. Mevalonate diphosphate
decarboxylase (MDD) catalyzes formation of isopentenyl
5-diphosphate in an ATP-dependent irreversible reaction
and is therefore an attractive target for inhibitor develop-
ment that could lead to new antimicrobial agents. To facili-
tate exploration of this possibility, we report the crystal struc-
ture of Staphylococcus epidermidis MDD (1.85 Å resolution)
and, to the best of our knowledge, the first structures of ligan-
ded MDD. These structures include MDD bound to the
mevalonate 5-diphosphate analogs diphosphoglycolyl pro-
line (2.05 Å resolution) and 6-fluoromevalonate diphosphate
(FMVAPP; 2.2 Å resolution). Comparison of these structures
provides a physical basis for the significant differences in Ki
values observed for these inhibitors. Inspection of enzyme/
inhibitor structures identified the side chain of invariant
Ser192 as making potential contributions to catalysis. Signifi-
cantly, Ser3Ala substitution of this side chain decreases kcat
by 103-fold, even though binding interactions between
FMVAPP and this mutant are similar to those observed with
wild type MDD, as judged by the 2.1 Å cocrystal structure of
S192A with FMVAPP. Comparison of microbial MDD struc-
tures with those ofmammalian counterparts reveals potential
targets at the active site periphery that may be exploited to
selectively target the microbial enzymes. These studies pro-
vide a structural basis for previous observations regarding the
MDD mechanism and inform future work toward rational
inhibitor design.
The ever-growing trend among many bacterial pathogens
toward antibiotic resistance represents one of the single great-
est threats to public health in both developing and modern
nations. In particular, a growing body of literature from the last
decade has demonstrated that many strains of the widespread
Gram-positive organisms Staphylococcus aureus and Staphylo-
coccus epidermidis are now insensitive toward an array of the
-lactam class antibiotics that were once considered frontline
therapeutics (1, 2). As recently as a few years ago, the problemof
antibiotic resistance was associated primarily with those infec-
tions arising from within the healthcare setting. However,
recent studies have shown that resistant strains are now spread-
ing rapidlywithin the community, where theymay cause poten-
tially life-threatening illness in persons not recently hospital-
ized or undergoing invasive medical procedures (1, 3). Given
the limited nature of effective therapeutic tools to combat these
diseases, all such infections must be carefully managed to pre-
vent further spread throughout the population. As a conse-
quence, there is now renewed interest in novel classes of anti-
microbials that are effective against sensitive and resistant
strains alike.
In all eubacteria, the C55 polyisoprenoid molecule undeca-
prenyl phosphate is an essential intermediate in the biosynthe-
sis of the peptidoglycan polymer that comprises an integral
component of the cell wall. As a polyisoprenoid, undecaprenyl
phosphate is synthesized in stepwise fashion from the building
block isopentenyl 5-diphosphate (IPP).5 Whereas IPP is gener-
ated via the methylerythritol phosphate pathway in Gram-neg-
ative organisms (4), many Gram-positive pathogens (including
those mentioned above) rely on the mevalonate pathway for its
synthesis (5). The mevalonate pathway produces one molecule
of IPP from three molecules of acetyl-CoA in six enzymatic
steps. Of these, five have been shown to be essential for the
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growth of various Gram-positive organisms (5), presumably
because of their requirement for providing IPP groups needed
for synthesis of menaquinone (for ATP production) as well
as undecaprenyl phosphate (for peptidoglycan production).
Because compounds that selectively inhibit any of the enzy-
matic reactions required for bacterial cell wall biogenesis have
been recognized for their potential value as antimicrobial
agents, the enzymes of the mevalonate pathway present new,
attractive targets for the identification and development of
next-generation antibiotics. Importantly, these targets have not
yet been exploited for such purposes, making it very likely that
potential drug candidates will have activity against resistant
strains of Gram-positive pathogens.
The enzyme mevalonate diphosphate decarboxylase (MDD;
EC 4.1.1.33) catalyzes the final step of the mevalonate pathway,
where it produces IPP from mevalonate 5-diphosphate
(MVAPP) in an irreversible reaction dependent upon Mg2-
ATP. The reaction proceeds as shown in Reaction 1. As the
mevalonate pathway is present in fungi, protists, and higher
eukaryotes, the MDD reaction is well established, and MDD
enzymes have been extensively characterized from yeast (6, 7),
avian (8), and mammalian sources (9–11). Together, these
results have elucidated many details of the MDD mechanism.6
In particular, the side chain of Asp283 has been assigned the role
of a general base, which serves to deprotonate the MVAPP C3
alcohol and to promote formation of a metastable 3-phospho-
MVAPP adduct. Departure of this phosphoryl leaving group
allows a carbocation intermediate to develop at C3. It is this, in
conjunction with interactions between the C1 carboxylate and
the guanidinium group Arg144, that drives subsequent decar-
boxylation and production of IPP. Indeed, mutation of either of
these side chains results in a 3–5 order ofmagnitude decrease in
catalysis (7, 11).
MDD proteins are members of the galactokinase, homoser-
ine kinase, mevalonate kinase, and phosphomevalonate kinase
(GHMP kinase) family (12). These enzymes are characterized
by a cone-shaped fold, where the -grasp-like N-terminal
region packs orthogonally against the relatively planarC-termi-
nal region comprised of five prominent -helices (13). High
resolution crystal structures of MDD proteins have been
reported from a number of species across several kingdoms of
life, including S. aureus (13), Trypanosoma brucei (13), Saccha-
romyces cerevisiae (12), as well as Homo sapiens (11). These
structures reveal the presence of a deep cleft that forms
between the roughly equal halves of the enzyme, which houses
the catalytic Asp and Arg residues. Despite the importance of
this work, a significant limitation of all MDD structures pub-
lished to date is the absence of any bound ligands at the active
site. Consequently, a detailed and direct identification of sub-
strate-binding residues has remained elusive.
To clarify previous observations regarding the MDD mech-
anism and to better understand the basis for substrate recogni-
tion byMDD proteins, we report here the high resolution x-ray
crystal structures of S. epidermidis MDD both free and bound
to the inhibitory substrate analogs diphosphoglycolyl proline
(DPGP) and 6-fluoromevalonate diphosphate (FMVAPP). In
addition to providing a physical basis for differences in inhibi-
tory potency between these two molecules, this work has iden-
tified a new residue, Ser192, that contributes to catalysis by
MDD. Furthermore, a significant sequence/structure differ-
ence between bacterial and eukaryotic MDDs at position 193
has also been identified. These studies inform structure/func-
tion relationships and highlight subtle yet noteworthy differ-
ences within diverse MDD proteins. The results will inform
future work on developing selective MDD inhibitors that may
be evaluated for their antimicrobial properties.
EXPERIMENTAL PROCEDURES
Cloning, Overexpression, and Purification of Recombinant
Forms of MDD—A gene fragment encoding the entire open
reading frame (residues 1–327) of MDD was amplified from S.
epidermidis genomic DNA via PCR and subcloned into the
expression plasmid pT7HMT (14). Upon confirmation of its
DNA sequence, this plasmid was transformed into BL21 (DE3)
Escherichia coli cells, and the resulting strain was cultured in
Terrific Broth supplemented with kanamycin (50 g/ml) at
37 °C to anA600 nm of 0.8. Protein expressionwas induced over-
night at 18 °C by adding isopropyl 1-thio--D-galactopyrano-
side to a 1 mM final concentration. Bacterial cells were har-
vested by centrifugation, resuspended in lysis buffer (20 mM
Tris-HCl (pH 8.0), 500 mM NaCl, and 10 mM imidazole), and
then lysed bymicrofluidization. The soluble tagged protein was
collected in the supernatant following centrifugation of the cell
homogenate and purified on a Ni2-NTA-Sepharose column
according to published protocols (14). Recombinant tobacco
etch virus (TEV) protease was used to digest the fusion affinity
tag from the target protein; however, following removal of the
affinity tag, the sequence GSTGS remains at the enzyme N ter-
minus as an artifact of the subcloning procedure. After desalt-
ing into 20 mM Tris-HCl (pH 8.0), final purification was
achieved by ResourceQ anion-exchange chromatography (GE
Healthcare). Following this, the purified protein was concen-
trated to 5 mg/ml and buffer exchanged by ultrafiltration into
10 mM Tris-HCl (pH 7.5), 50 mM NaCl, and stored at 4 °C for
further use. An analogous expression vector for the S192A
mutant was constructed using standard molecular biology
techniques (15). Themutant enzymewas purified and stored in
an identical manner to the wild type protein.
Substrates and Analogs—The synthesis of MVAPP has been
previously reported (16) and is briefly summarized. Methyl
3-hydroxy-3-methyl-5-iodopentanoate was synthesized by
reacting mevalonolactone with trimethylsilyl iodide, followed by
diazomethane derivatization to form the methyl ester. The prod-
uct was subsequently purified by silica gel chromatography.
Methyl 5-diphosphomevalonate was synthesized by reacting the
purified methyl 3-hydroxy-3-methyl-5-iodopentanoate with an
6 Numbering of all residues in this work reflects their position in the S. epider-
midis MDD sequence.
REACTION 1
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excess of tetrabutylammonium diphosphate. This material was
purified using a DEAE-Sephadex A-25 (bicarbonate form) col-
umn.The purifiedmethyl 5-diphosphomevalonatewas converted
to the lithiumsalt usingDowex50 (lithium form).Deesterification
was accomplished by alkaline hydrolysis in 0.5 N LiOH for 20 h at
4 °C. The pHwas adjusted to8.0with coldHCl, and the concen-
trationof thephysiologically activeR isomerwasdeterminedusing
MDD for an enzymatic end point assay.
Preparation of FMVAPP employed the method described by
Voynova et al. (11). Five milligrams (33.8 mol) of (RS)-6-fluo-
romevalonolactone was delactonized in 0.1 N KOH by incuba-
tion for 1 h at 37 °C prior to neutralization. The reaction mix-
ture for the formation of FMVAPP included the following in 1.5
ml: 30 mM Tris-HCl (pH 7.5), 22.5 mM (RS)-6-fluoromeval-
onate, 5 mM ATP, 6 mM MgCl2, 0.7 mM DTT, 50 mM phospho-
enolpyruvate, 6 units of pyruvate kinase, and 2.7 units ofmeval-
onate kinase. The reaction was incubated at 30 °C. 16.9mol of
(R)-6-fluoromevalonate were converted to themonophosphate
in 1 h as determined by a phosphomevalonate kinase end point
assay. Phosphomevalonate kinase (4 units of human enzyme)
was then added, and the incubation was continued at 25 °C for
12 h. 10 mol (60%) of the (R)-6-fluoromevalonate 5-phos-
phate was converted to the diphosphate as determined with
phosphomevalonate kinase (reverse reaction). The reaction
mixturewas deproteinized (95 °C for 3min), cooled to 0 °C, and
centrifuged for 15 min at 16,100  g, and the supernatant was
adjusted to pH 5.0. Nucleotides were precipitated with cold
ethanol (65% v/v for 30 min). Ethanol was removed from the
supernatant by evaporation, and the sample was adjusted to pH
8.0 prior to dilution and chromatographic purification
(DEAE Sephadex A-25).
The competitive inhibitor DPGP was synthesized by the
strategy of Vlattas et al. (18). Detailed methodology has been
described by Krepkiy and Miziorko (19).
Kinetic Characterization ofWild Type andMutant S. epider-
midis MDD—Enzymatic activity was determined using a spec-
trophotometric assay coupling product ADP formation to
pyruvate kinase/lactate dehydrogenase oxidation of NADH at
340 nm using a PerkinElmer Life Sciences 35 spectrophotome-
ter. Assays were performed at 30 °C in 100 mM HEPES-NaOH
(pH7.0) containing 100mMKCl, 10mMMgCl2, 0.2mMNADH,
0.4 mM phosphoenolpyruvate, and 4 units each of pyruvate
kinase and lactate dehydrogenase. All assays were initiated by
addition of MVAPP. Vmax and Km values (Table 1) were deter-
mined by fitting data to the Michaelis-Menten equation. For
inhibition kinetics, substrate (MVAPP)was varied versus inhib-
itor concentrations for FMVAPP or DPGP. Optimal data fits
(R2 0.97) were obtained using either competitive (FMVAPP)
or mixed (DPGP) inhibition models. All kinetic data analysis was
performed using SigmaPlot 10.0/Enzyme Kinetics Module 1.3
(Systat Software, Inc.). FMVAPP concentrations varied from 40
to 320 nM. DPGP concentrations varied from 3 to 10 M.
Crystallization—Recombinant S. epidermidis MDD was
crystallized by vapor diffusion of hanging drops at 20 °C. Spe-
cifically, 1 l of protein solution (5 mg/ml in 10 mM Tris-HCl
(pH 7.5), 50mMNaCl) wasmixedwith 1l of reservoir solution
containing 0.25M sodium formate and 16% (w/v) PEG3350 that
had been previously diluted in an equal volume of double dis-
tilled H2O and equilibrated over 500 l of reservoir solution.
Single block-shaped crystals appeared after 2 days and contin-
ued to grow in size for 3 days. Crystals were flash-cooled in a
cryoprotectant solution consisting of reservoir buffer with an
additional 15% (v/v) glycerol. Cocrystallization of MDD with a
molar excess (0.5 mM) of both DPGP and FMVAPP was
achieved in the same manner as described above. Cocrystals of
the S192A mutant MDD bound to FMVAPP were obtained in
the same manner as for wild type MDD.
DiffractionDataCollection, StructureDetermination, Refine-
ment, and Analysis—Monochromatic x-ray diffraction data
were collected from single crystals at 100 K using beamline
22-BMof theAdvancedPhoton Source,ArgonneNational Lab-
oratory (Table 2). Following data collection, individual reflec-
tions were indexed, integrated, merged, and scaled using
HKL2000 (20). Initial phase information was obtained for the
unbound MDD structure by maximum-likelihood molecular
replacement using PHASER (21). Specifically, chain A of PDB
entry 2HK2 (S. aureus MDD) was altered using the SWISS-
MODEL server to reflect the sequence of S. epidermidisMDD
(22, 23), and the resulting hypothetical structure was used as a
searchmodel. The singlemost highly scored solution contained
an MDD dimer in the asymmetric unit; this arrangement cor-
responded to a Matthews coefficient of 2.23 Å3/Da and a sol-
vent content of 45.0%. The refined structure of unliganded
MDD (as obtained below) was used as a search model for all
other structures reported here.
Structure refinement was carried out using phenix.refine
(24). One round of simulated annealing, individual coordinates,
and isotropic atomic displacement factor refinement were con-
ducted, and the refinedmodel was used to calculate both 2Fo 
Fc and Fo  Fc difference maps. These maps were used to iter-
atively improve the model by manual building in Coot (25, 26),
followed by additional coordinate and atom displacement fac-
tor refinement. A final cycle of TLS refinement was also used to
complete the structure of wild type MDD bound to FMVAPP.
Ordered solventmolecules were added to all structures accord-
ing to the default criteria of phenix.refine and inspected man-
ually using Coot prior to model completion. Additional infor-
mation and refinement statistics for all four structures are
presented in Table 2.
With the lone exception of chain A in the DPGP-bound
structure, a region of poor map quality exists between residues
184 and 194 in all MDD structures reported here. The exact
number of residues that could not be modeled ranged between
two and six, varying among the chains and structures. Further
details regarding the residues that could not be modeled accu-
rately may be found in the corresponding PDB files.
Ligand Fitting—Models for each ligandwere generated using
the PRODRG server (27), and restraint files were generated
using phenix.elbow (24). In all cases reported here, inspection
of the initial Fo  Fcmaps described above revealed unmodeled
contiguous density that corresponded to ordered ligand in the
active site of both copies of MDD found within the asymmetric
unit. phenix.ligandfit (24) was subsequently used to fit and
model an inhibitor molecule in each active site. Refinement of
inhibitor-bound MDD structures was carried out as described
above, with the exception that constrained group occupancy
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refinement was used to estimate the fraction of ligand bound at
each site independently.
Miscellaneous—Multiple sequence alignments were carried
out using ClustalW (28) and aligned with secondary structure
elements using ESPRIPT (29). MDD sequences used in align-
ments, along with their respective GenBankTM accession num-
bers, were as follows: S. epidermidis, 27467280; S. aureus,
14246359; Legionella pneumophila subsp. pneumophila,
52842257; Streptococcus pyogenes, 5093120; H. sapiens,
4505289; S. cerevisiae, 1706682; T. brucei, 149241992; Mus
musculus, 13539580; Listeria monocytogenes, 217965923;
Enterococcus faecalis, 315577315; Xenopus (Silurana) tropica-
lis, 39645379; Bos taurus, 115495513; Arabidopsis thaliana,
18410026. Three-dimensional structures were superimposed
using the Local-Global Alignment method (LGA) (30). MDD
structures were obtained from the PDB (31) and are as follows:
S. cerevisiae (1FI4); S. pyogenes (2GS8); S. aureus (2HK2 and
2HK3); T. brucei (2HKE); H. sapiens (3DJ4); M. musculus
(3F0N); L. pneumophila (3LTO). Representations of all struc-
tures were generated using PyMol (32). Calculations of electro-
static potentials at themolecular surface were carried out using
DELPHI (33, 34). The program CONSURF was used to plot
levels of amino acid sequence conservation on the molecular
surface (35).
RESULTS
Kinetic Characterization and Crystal Structure of MDD from
S. epidermidis—Whereas MDD proteins have been previously
described froma variety of organisms, the nature of this enzyme
in the pathogen S. epidermidis has so far been undetermined.
To this end, a BLAST search was conducted using S. aureus
MDD as a query sequence (36), which identified an as yet
uncharacterized protein that shared 73% identity across the
entire 327-residue polypeptide. A cDNA corresponding to this
open reading frame was amplified by S. epidermidis genomic
DNA by PCR and subcloned into an expression vector, and the
resulting protein was expressed recombinantly and isolated
from E. coli. The purified protein was characterized using the
assay described under “Experimental Procedures.” The results
of this analysis demonstrated that this S. epidermidis protein is
a bona fideMDD that exhibits kinetic constants of Vmax  9.8
units/mg,Km,(RS)-MVAPP  9.1M, andKm(ATP)  27M (Table
1). These values are comparable to corresponding parameters
reported for most other MDD enzymes, although the prokary-
otic MDD enzymes exhibit lower Km values for ATP than
reported for eukaryotic enzymes. In all cases,Ki(FMVAPP) (100
nM) indicates high affinity binding, whereas the analog DPGP
inhibits 40–90-fold more weakly to human and S. epidermidis
MDD, respectively (Fig. 1 and Table 1). Table 1 also includes
kinetic parameter data for previously uncharacterized
S. aureus and T. brucei MDD proteins (for which unliganded
structures have been determined (13)), demonstrating that
these proteins efficiently catalyze the MDD reaction.
To better understand the nature of this enzyme, purified S.
epidermidiswas entered into crystallization trials using a hang-
ing drop vapor diffusion approach. Following optimization of
initial crystals, the final samples diffracted synchrotron x-rays
FIGURE 1. Inhibition of S. epidermidis MDD by MVAPP analogs. Double-reciprocal plots of MDD activity versus substrate MVAPP concentration are shown as
measured in the presence of either DPGP or FMVAPP. A, inhibition of MDD by DPGP. Concentrations of DPGP are as follows: 0 M (F), 3 M (E), 5 M (), 7 M
(ƒ), and 10 M (f). B, inhibition of MDD by FMVAPP. Concentrations of FMVAPP are as follows: 0 nM (F), 40 nM (E), 80 nM (), 160 nM (ƒ), and 320 nM (f).
Concentrations of substrate (MVAPP) were 2.5, 5, 10, 20, and 40 M in both panels. Optimal fits to the data were obtained using a mixed inhibition model in A
and a competitive inhibition model in B.
TABLE 1
Comparison of kinetic parameters for MDD from S. epidermidis and other sources
Parametera S. epidermidisMDD S. epidermidis S192A S. aureusMDD T. bruceiMDD H. sapiensMDDb Gallus gallusMDDc
Vmax (units/mg) 9.8 	 0.3 0.0096 	 0.0003 9.8 	 0.2 8.8 	 0.2 6.1 	 0.5 6.3
kcat (s1) 5.9 	 0.2 0.0058 	 0.0002 6.0 	 0.1 6.1 	 0.1 4.4 	 0.4 4.5
Km((RS)-MVAPP) (M) 9.1 	 0.9 5.0 	 1.0 22.3 	 1.6 6.0 	 0.4 28.9 	 3.3 14.1
Km(ATP) (mM) 0.027 	 0.003 0.07 	 0.01 0.013 	 0.001 0.30 	 0.02 0.69 	 0.07 0.50
Ki((R)-FMVAPP) (nM) 49 	 5 ND ND 22.8 	 3.8 62 	 5 ND
Ki((RS)-DPGP) (M) 4.3 	 1.0d ND ND ND 2.3 	 0.3 ND
a ND indicates value has not been determined.
b Estimates were reported by Voynova et al. (11).
c Estimates were reported by Alvear et al. (8).
d Ki slope value is reported. Mixed (noncompetitive) inhibition was observed.
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to 1.85 Å resolution (Table 2). The S. epidermidisMDD struc-
ture was solved by molecular replacement and subsequently
refined to final Rwork and Rfree values of 19.5 and 22.7%, respec-
tively (Fig. 2A). This structure adopts a canonical GHMPkinase
fold and displays a high degree of homology to those of related
MDD proteins (Fig. 2B), even though these enzymes collec-
tively share a rather limited sequence identitywith one another.
For example, S. epidermidisMDD is only 34% identical with the
human enzyme, yet 300 of its 327 backbone atoms superimpose
at less than 4.0 Å distance of their corresponding positions with
a root mean square deviation of 1.54 Å (30).
S. epidermidis MDD behaves as a dimer of 36-kDa subunits
in analytical gel filtration chromatography experiments (sup-
plemental Fig. S2). Consistent with this, the MDD polypeptide
is found as a dimer within the asymmetric unit of its centered
orthorhombic crystal. This quaternary structure buries 1950Å2
or nearly 7% of the available surface area when both protein
chains are considered together. This is comparable to the
observation of a dimer interface of 7.7% (2250Å2) for ratmeval-
onate kinase (37), which also exhibits the GHMP kinase fold.
Although examination of neighboring asymmetric units reveals
the presence of alternative modes for dimerization, only this
interface is predicted to be significantly thermodynamically
favored in solution, as judged by the protein interface surfaces
and assemblies (PISA) server (38). These considerations aside,
the entrance to the active site cavity is unhindered by any of the
potential dimerization contacts described here. Thus, although
observation of a dimeric species forMDD is typical, it is unclear
that a dimeric enzyme is required for catalysis.
Structural Basis for Substrate Recognition and Competitive
Inhibition of MDD—Prior crystallographic studies on MDD
proteins have been limited to the unliganded form of the
enzyme, which has precluded detailed analysis of both their
structure/function relationships and modes of substrate bind-
ing. In two cases in particular (i.e. S. aureus and T. brucei (13)),
attempts to obtain an informative ligand-bound structure were
unsuccessful, presumably because of the presence of well
ordered sulfate ions found within the purported active site cleft
of these enzymes (13). Examination of additional MDD struc-
tures available in the PDB suggests that moderate to high con-
centrations of sulfate anions indeed promote crystallization of
these enzymes, as five of the seven structures resulted from
crystals harvested from sulfate-containing mother liquids. In
this regard, the fact the crystals of S. epidermidis MDD grow
readily in the absence of sulfate raised the possibility that this
specific enzyme may be more amenable to determination of a
structure with bound ligand.
Previous investigation into the MDDmechanism has identi-
fied two separate diphosphorylated compounds, DPGP (11)
and FMVAPP (16, 39), that mimic the MVAPP substrate and
competitively inhibit MDD activity (11). Despite these similar-
ities, characterization of their effects on S. epidermidis MDD
TABLE 2
Diffraction data collection and structure refinement statistics
Data collectiona
Crystal MDD MDD  DPGP MDD  FMVAPP S192A  FMVAPP
Beamline APS 22-BM APS 22-BM APS 22-BM APS 22-BM
Wavelength 1.000 Å 1.000 Å 0.9724 Å 1.000 Å
Space group C2221 C2221 C2221 C2221
Cell dimensions a  82.98 a  82.67 a  82.80 a  82.50
b  101.99 b  101.44 b  101.49 b  101.37
c  155.77 c  154.64 c  155.56 c  155.26
Resolution 26.91-1.85 Å 29.60-2.05 Å 30.70-2.20 Å 29.00-2.10 Å
Reflections (unique) 307, 824 (52,638) 573,361 (41,249) 486,156 (33,608) 211,067 (34,043)
Completeness 92.7% (81.5%) 100.0% (100.0%) 100.0% (99.9%) 88.8% (87.5%)
Redundancy 5.8-Fold 13.9-Fold 14.5-Fold 6.2-Fold

I/
I 25.2 (2.5) 26.6 (5.1) 20.0 (5.0) 19.5 (2.9)
Rmergeb 5.8% (60.3%) 9.1% (50.5%) 10.9% (46.0%) 7.9% (53.2%)
Refinement
PDB code 3QT5 3QT6 3QT7 3QT8
Protein molecules/asymmetric unit 2 2 2 2
Rwork/Rfreec 19.5/22.7% 18.3/22.6% 17.8/22.5% 19.0/24.1%
No. of atoms
Protein 5078 5078 5038 5065
Ligand NAd 40 38 38
Solvent 389 312 243 284
Ramachandran plot
Favored 98.1% 98.1% 98.1% 98.4%
Allowed 1.7% 1.6% 1.4% 1.6%
Outliers 0.2% 0.3% 0.5% 0%
Root mean square deviation
Bond length 0.007 Å 0.008 Å 0.007 Å 0.008 Å
Bond angle 0.99° 1.03° 1.07° 1.09°
B factor
Protein 27.1 Å2 31.2 Å2 33.0 Å2 32.0 Å2
Ligand NA 30.0 Å2 25.1 Å2 26.2 Å2
Solvent 30.2 Å2 33.5 Å2 33 Å2 32.0 Å2
Ligand occupancy
Chain A NA 80% 100% 100%
Chain B NA 92% 100% 100%
a Numbers in parentheses are for the highest resolution shell.
bRmerge  hiIi(h)  
I(h)/hiIi(h), where Ii (h) is the ith measurement of reflection h, and 
I(h) is a weighted mean of all measurements of h.
c R  hFobs(h)  Fcalc(h)/hFobs. Rcryst and Rfree were calculated from the working and test reflection sets, respectively. The test set constituted 5% of the total reflections
not used in refinement.
d NAmeans not applicable.
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revealed markedly different Ki values of 4 M for DPGP and
49 nM for FMVAPP (Table 1). A similar trend was also
observed for the same inhibitors and human MDD, where
the observed Ki values were 2 M and 62 nM, respectively.
Because comparison of Ki values for competitive inhibitors
and Ki slope values for mixed inhibitors primarily reflects dif-
ferences in binding affinity, these data suggested that mean-
ingful insight into both the catalytic mechanism andmode of
substrate binding by MDD proteins could be revealed by
determining the cocrystal structures of S. epidermidis MDD
bound to DPGP and FMVAPP.
Crystals of MDD grown in the presence of (RS)-DPGP dif-
fracted x-rays to 2.05 Å limiting resolution (Table 2). Following
modeling and refinement of two copies of MDD, analysis of an
Fo  Fc difference map revealed a region of strong contiguous
density within the MDD active site cleft (Fig. 3A) (11). Place-
ment and refinement of a single (R)-DPGP molecule per
enzymemonomer (occupancy of 0.80 and 0.92 in chainAandB,
respectively) are in good agreement with the observed diffrac-
tion data (Table 2 and Fig. 3B). Significantly, the conformations
of both (R)-DPGP molecules, bound selectively from the R,S
mixture, are nearly indistinguishable fromone another, as all 24
FIGURE 2. 1.85 Å crystal structure of apo-MDD from S. epidermidis. A, crystal structure of S. epidermidis MDD shown in ribbon format. Two copies of
MDD are found within the asymmetric unit and are colored blue (N terminus) and red (C terminus). B, stereo view of MDD structures in ribbon format
deposited within the PDB. Structures correspond to the following organisms: S. epidermidis (red-orange); S. aureus (cyan); L. pneumophila (orange); S.
pyogenes (red); H. sapiens (yellow-green); S. cerevisiae (blue); T. brucei (green); and M. musculus (yellow). C, limited structure-based sequence alignment of
prokaryotic and eukaryotic MDD proteins. Alignment was generated using ClustalW and rendered with ESPRIPT. Numbers above the sequences corre-
spond to S. epidermidis MDD. Red stars below the sequences correspond to invariant amino acid side chains involved in DPGP and FMVAPP interaction,
and the green star represents the single variable active site residue. Sequences from B as well as the following were used in alignment: L. monocytogenes;
E. faecalis; Xenopus. tropicalis; B. taurus; A. thaliana.
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atoms modeled superimpose with root mean square deviation
values of 0.75 Å (Fig. 3C).
Numerous invariant amino acid side chain and backbone
atoms contribute to the strong interaction ofMDDwith DPGP
(Figs. 2C and 3D and supplemental Fig. S1). Several of these,
including four serines (Ser107, Ser 139, Ser141, and Ser192), two
residues from the N-terminal most -strand in the enzyme
(Tyr18 and Lys21), as well as Gly140 and Arg193 lie within a 3.5 Å
distance of the atoms that comprise the - and -phosphoryl
groups of DPGP. Separately, both nitrogen atoms of the cata-
lytic Arg144 guanidinium group hydrogen bond with a single
oxygen atom from theDPGP carboxylate (2.8 and 3.1Å, respec-
tively). Finally, while the available carbonyl oxygen of DPGP is
also close enough to hydrogen bond with the side chain of
Ser192 (3.2 Å), the general base Asp283 is notable in that it is too
distant to interact with any atoms of the inhibitor.
In a similar manner, MDD crystals were grown in the pres-
ence of (R)-FMVAPP. These crystals diffracted x-rays to 2.20 Å
limiting resolution (Table 2).Well defined electron density was
likewise apparent upon inspection of the Fo Fcdifferencemap
obtained following initial refinement (Fig. 4A). A single copy of
FMVAPP was placed in each MDD active site and refined at
100% occupancy (Table 2 and Fig. 4B). As was seen for DPGP,
both FMVAPP molecules are bound in identical conforma-
tions, as all 19 atoms modeled superimpose with a root mean
square deviation of 0.72 Å (Fig. 4C). Although several recurring
side chain and backbone contacts from the DPGP-bound
enzyme are present in the FMVAPP-inhibited structure (Figs.
2C, 3D, and 4D and supplemental Table S1), other unique inter-
actions are also observed. For example, the backbone nitrogen,
rather than the side chain hydroxyl, of Ser107 participates in a
hydrogen bond with an -phosphoryl-derived oxygen atom of
FVMAPP (Fig. 4, D and E). Furthermore, several interactions
that are crucial to the proposed catalytic mechanism are also
seen. This includes a hydrogen bond (3.4 Å distance) between
the side chain of Asp283 and C3 hydroxyl of FMVAPP, and each
of the nitrogen atoms of the Arg144 guanidinium group binds to
a different oxygen of the FMVAPP C1 carboxylate (2.9 and 3.1
Å). Finally, the fluoromethyl group of FMVAPP participates in
an F(H–N)hydrogen bond (3.1Å)with the backbone amine of
Ala284.
Identification of Ser192 as New Residue That Contributes to
MDD Catalysis—Earlier structure/function studies on MDD
proteins have identified residues Asp283 (7) and Arg144 (11) as
playing essential roles in catalysis. Furthermore, mutagenesis
studies on Ser139 and Ser141 strongly suggest the influence of
these residues in binding the diphosphorylated substrate
MVAPP (19). Whereas these roles are readily interpreted in
light of the DPGP- and FMVAPP-bound structures described
above, the contributions of other residues are less certain. One
such residue is Ser192, which is also invariant among a large and
diverse cohort of MDD proteins (supplemental Fig. S1).
Ser192 is positioned on the opposite side of the active site cleft
from Ser139 and Ser141, whose side chains participate directly in
substrate binding. Nevertheless, Ser192 is also a far distance
from the MVAPP atoms whose bonding patterns are altered
during theMDD reaction, which suggests a role for this residue
in substrate binding. Consistent with this idea, this side chain
participates in hydrogen bonds with atoms from the inhibitor
-phosphoryl group in both the DPGP- and FMVAPP-bound
structures. To test the role of Ser192 more directly, a S192A
mutant of S. epidermidisMDDwas constructed and character-
FIGURE 3. 2.05 Å cocrystal structure of MDD bound to the inhibitor DPGP. A, Fo  Fc map (green mesh at 2.0 contour) of the refined structure in the ab-
sence of modeled ligand. Active site side chains within interaction distance are depicted in ball and stick format (cyan). MDD backbone is depicted in ribbon
format (purple). B, 2Fo  Fc map (blue mesh at 2.0 contour) of the refined structure with one molecule DPGP modeled per enzyme. Color scheme is the same
as A, with DPGP colored yellow. C, overlay of DPGP molecules from the active sites of chains A (yellow) and B (cyan). D, active site side chains within 2.6 –3.4 Å
of DPGP. Further information on these distances can be found in supplemental Table S1.
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ized. Mutagenic substitutions of this side chain resulted in a
near wild type Km value for substrate binding (Table 1), a fea-
ture that agrees well with the 2.10-Å cocrystal structure of
FMVAPP bound to this mutant enzyme (Fig. 5A and Table 2).
Despite these similarities, however, the mutant exhibited a
greater than thousand-fold loss of catalytic activity (kcat) (Table
1). Although a detailed explanation for this effect may require a
ternary ATP-FMVAPP-MDD structure, it is noteworthy that
distances between the established catalytic residues (Asp283
and Arg144) and their cognate groups on FMVAPP are greater
FIGURE 4. 2.20 Å cocrystal structure of MDD bound to the inhibitor FMVAPP. A, Fo  Fc map (green mesh at 3.0 contour) of the refined structure in the
absence of modeled ligand. Active site side chains within interaction distance are depicted in ball and stick format (cyan). MDD backbone is depicted in ribbon
format (purple). B, 2Fo  Fc map (blue mesh at 2.0 contour) of the refined structure with one molecule FMVAPP modeled per enzyme. Color scheme is the same
as A, with FMVAPP colored yellow. C, overlay of FMVAPP molecules from chains A (yellow) and B (cyan). D, active site side chains within 2.6 –3.4 Å of FMVAPP.
Further information on these distances can be found in supplemental Table S2. E, overlay of the MDD active site from cocrystal structures of DPGP (green) and
FMVAPP (yellow). Active site side chains from the FMVAPP cocrystal structure are depicted in ball and stick format (cyan).
FIGURE 5. 2.10 Å cocrystal structure of MDD mutant S192A bound to the inhibitor FMVAPP. A, active site side chains within 2.6 –3.6Å of FMVAPP are
depicted in ball and stick format (cyan). Further information on these distances can be found in supplemental Table S2. MDD backbone is depicted in ribbon
format (purple). B, overlay of FMVAPP molecules from wild type MDD (green) and mutant S192A MDD (yellow). Color scheme is the same as A.
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in the mutant cocrystal structure when compared with wild
type MDD (Fig. 5B and supplemental Table S2). Furthermore,
the dihedral angle between the Arg144 guanidinium group and
the FMVAPP C1 carboxylate is noticeably steeper in the
mutant structure relative to that of wild type (29.3 	 1.6°
versus 18.4 	 2.8°, respectively).
Conservation and Divergence in the Vicinity of the MDD
Active Site Cleft—The dual substrate nature of MDD (i.e.
MVAPP and ATP) places strict requirements on the solvent
accessibility of the enzyme active site. This is magnified by the
polyanionic nature of the substrates, which together carry a
formal charge of8 at physiological pH values. Consistentwith
these limitations, the residues lining the MDD active site
entrance are overwhelmingly electropositive, and the charge
density in this area is a striking feature of theMDD surface (Fig.
6A). The importance of this positively charged patch to sub-
strate binding is likewise underscored by evolutionary analysis
of surface-exposedMDD residues.Whereas much of theMDD
surface exhibits variable levels of sequence conservation, the
entrance to the active site cleft is practically invariant since the
divergence of bacteria and humans (Fig. 6B).
The many conserved features of the MDD mechanism are
highlighted by high levels of identity among residues found in
the active sites of variousMDDproteins.However, the ability to
identify and develop highly selective competitive inhibitors
requires some level of divergence between target enzymes (i.e.
those found in bacterial cells) and those found in the human
host. In this regard, examination of microbial MDD sequences
and structures alongwith those from their protozoan,mamma-
lian, and human counterparts reveals one obvious and signifi-
cant difference within the active site (Figs. 6C and 2C and
supplemental Fig. S1). Specifically, although higher order
organisms have a Thr at the equivalent position to residue 193,
bacterial enzymes instead harbor an Arg at this location. It is
worth noting that the side chain of Arg193 is well ordered in all
cocrystal structures determined here (e.g. average atomic B fac-
tor of 27.9 Å2 relative to the mean value of 33.0 Å2 for protein
atoms in theMDD FMVAPP structure), as the atoms from its
guanidinium group facilitate binding to the -phosphoryl moi-
ety of both DPGP and FMVAPP. As a consequence, exploita-
tion of this particular amino acid substitution may allow for
future development of compounds that specifically target only
bacterial MDD proteins.
DISCUSSION
MDD is a member of the large GHMP kinase family of pro-
teins, which includes not only phosphoryl transfer enzymes but
also proteins involved in development. A recent article (40) on
a bacterial threonine kinase, which fits into this protein family,
pointed out that familymembers appear to use different kinetic
and catalytic mechanisms despite their common tertiary struc-
tures. These enzymes typically catalyze sequential reactions in
which ATP reacts with a phosphoryl acceptor to formADP and
a phosphorylated product. SomeGHMP kinases bind ATP first
and acceptor substrate second (e.g. liver galactokinase (41) and
Salmonella enterica threonine kinase (40)). By contrast, others
bind acceptor before ATP (e.g. liver mevalonate kinase (42) and
liverMDD (43). Yet others still appear to utilize a randomorder
of substrate binding in proceeding to a ternary reaction com-
plex (E. coli galactokinase (44) and Streptococcus pneumoniae
phosphomevalonate kinase (45). Based upon the crystal struc-
tures presented here, it seems unlikely that MDD could func-
tion through any mechanism other than binding the MVAPP
acceptor prior to ATP. This is because both the MVAPP-bind-
FIGURE 6. Conserved nature of the active site cleft. A, surface representation of electrostatic potential, generated by DelPhi, of chain A from MDD bound to
FMVAPP (cyan). Color scheme represents regions of negative (red) and positive (blue) charge density contoured at 	5 e/kT. B, conservation plot of surface-
exposed MDD amino acid side chains from S. epidermidis, as generated by CONSURF. Color scheme depicts variable (blue to green), average (yellow), and strong
(orange to red) conservation. C, conserved nature of Arg193 (purple stick) within the active site of prokaryotic MDD proteins (backbone atoms colored cyan).
Superimposed MDD structures are from S. epidermidis, S. aureus, S. pyogenes, and L. pneumophila. D, conserved nature of Thr (cyan stick) in eukaryotic MDD
proteins (backbone atoms in purple) at the structurally equivalent position to Arg193. Superimposed MDD structures are from H. sapiens, M. musculus, T. brucei,
and S. cerevisiae. FMVAPP is shown in C and D according to its position in the wild type MDD  FMVAPP structure (Fig. 4).
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ing site and the catalytic residues of the enzyme lie at the bot-
tom of theMDD active site cleft. This active site cleft resembles
a funnel, rather than a shallow groove on the protein surface, so
there is no conceivable route to the catalytic site that would not
be greatly or completely occluded by binding to the compara-
tively larger nucleotide substrate. Still, a conclusive statement
regarding this aspect of MDD function will require determina-
tion of a ternary complex structure. However, these observa-
tions on MDD binary complexes are in accord with the kinetic
results of Jabalquinto andCardemil (43), whoproductively used
the dead-end competitive inhibitormethod (well established by
Fromm (46)) to distinguish between random, ordered, and
ping-pong kinetic mechanisms for MDD. They employed
mevalonate, mevalonate phosphate, ATPS, and AMP-PCP as
inhibitors and tested these against the substrates mevalonate
diphosphate and ATP. The inhibition patterns that were docu-
mented unambiguously established that MDD follows a
sequential kinetic mechanism in which mevalonate phosphate
binds before ATP. Thus, their results represent an important
test and provide independent confirmation of the structural
data.
Reports suggest that different catalytic mechanisms may be
used by the various GHMP kinases. For homoserine kinase,
there is no structural evidence for an active site base that would
enhance attack of acceptor substrate on the -phosphoryl of
ATP, so, by default, a direct nucleophilic attack mediated by
transition state stabilization has been proposed (47). For yeast
galactokinase, pH dependence results were interpreted to dis-
count any need for a catalytic base in this enzyme (48). Subse-
quently, these authors collaborated on a structural investiga-
tion of Pyrococcus furiosus galactokinase; the conclusions
suggested that an active site aspartate may indeed function as a
catalytic base (49). For two GHMP kinases in the mevalonate
pathway, we addressed this issue by interpreting structural
results in the context of functional data. In the case of ratmeval-
onate kinase, the binary enzyme-ATP structure indicates the
proximity between Asp204 to the -phosphoryl of ATP (37).
Mutagenesis results indicate that exchange of the aspartate car-
boxyl for either asparagine or alanine side chains that do not
function as a base reduces the catalytic rate by greater than
104-fold. Such an effect is appropriate inmagnitude for removal
of a catalytic base (50). Similarly, substitution of Asp302 in yeast
MDD with either asparagine or alanine results in 103- and
105-fold decreases in catalysis, respectively. Consistent with
these previous observations, the results reported here indicate
that the correspondingAsp283 is situated only 3.4Å from theC3
hydroxyl oxygen of FMVAPP. Thus, a functional assignment of
Asp283 as a catalytic base can now be justified on the basis of
both structural proximity and mutagenesis results. When con-
sidered together, the body of literature on both mevalonate
kinase andMDD strongly suggests that GHMP kinases include
a subclass of enzymes that do indeed utilize an active site base to
deprotonate the phosphoryl acceptor.
Perhaps there may be a reasonable alternative explanation
for the role of active site aspartates inmevalonate kinase,MDD,
and other GHMP kinase enzymes whose future characteriza-
tion may add to this mechanistic class. This hypothesis would
involve a role for aspartate in precisely positioning the substrate
so that the acceptor oxygen (i.e. C5 oxygen in mevalonate; C3
oxygen inmevalonate diphosphate) is optimally aligned for effi-
cient in-line phosphoryl transfer of the ATP -phosphoryl
group. Such an explanation (17) has been proposed to account
for the large diminution in catalysis (4,000-fold) that results for
mevalonate kinase upon alanine substitution of Ser146 which,
by hydrogen bonding, optimizes orientation of the phosphoryl
chain ofATP (37). It is therefore likely thatmore structural data
on GHMP kinase ternary complexes will allow a consensus to
develop regarding whether general base catalysis is operative or
whether substrate alignment accounts for observations such as
those documented for binary complexes of mevalonate kinase
and MDD. As such data develop for MDD, a more complete
understanding of binding differences of DPGP or FMVAPP to
MDD should become possible, although the difference in how
the carboxyl groups of these analogs interact with Arg144
already seems clear. That being said, previous functional char-
acterization of mutations at serines comparable to Ser139 and
Ser141 was not unambiguous, as these data indicated effects on
both phosphoryl acceptor and donor binding sites (19). In this
regard, Ser107 appears to interact with phosphoryl acceptors in
the binary complexes, albeit in slightly different ways, even
though precedent strongly suggests that this residue is situated
in a consensus binding motif for the ATP phosphoryl donor.
Here again, information obtained from a ternary complex
structure is likely to refine our understanding of these MDD-
binding site determinants.
Because several related taxa of important human pathogens
rely on the mevalonate pathway to provide the isoprenoid
building blocks necessary for ATP biosynthesis and for synthe-
sis and maintenance of the bacterial cell wall, the potential for
antibiotic discovery within this pathway remains both justified
and intriguing. In this regard, the absolute requirement of
MDD for a functionalmevalonate pathway renders this enzyme
an attractive target for such work. Because crystallographic
data can play a significant part in guiding inhibitor design, the
crystals and structures presented here constitute a promising
starting point for several reasons. First, the S. epidermidisMDD
crystals provide the opportunity to study an enzyme from the
biologically relevant situation (i.e. aGram-positive pathogen) at
relatively high resolution. Second, unlike the crystals described
for closely related proteins (e.g. S. aureusMDD), the S. epider-
midisMDDcrystals grow in a condition that is free of both high
concentrations of sulfate and phosphate anions. This serendip-
itous discovery prevents undesirable, adventitious binding of
such anions in a region of the active site that contributes impor-
tant determinants for recognizing the diphosphorylated sub-
strateMVAPP.Along similar lines, themodest ionic strength of
the precipitant solution (0.25 M sodium formate) appears to be
amenable to cocrystallization or ligand soaking of large num-
bers of potential small molecule inhibitors. In this respect,
determination of cocrystal structures with both DPGP and
FMVAPP, two molecules whose relative affinities for the
enzyme differ considerably, provides a valuable proof of princi-
ple moving forward. Finally, this approach has already uncov-
ered a significant difference between bacterial and eukaryotic
MDD active sites that may be important to designing selective
inhibitors. While this work is still ongoing, it represents an
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exciting basis fromwhich future structure-activity relationship
studies on small molecule inhibitors can be launched.
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SUPPLEMENTARY FIGURE LEGENDS 
 
Fig. S1.  Complete structure-based multiple sequence alignment of MDD proteins.  Alignment was 
generated using ClustalW.  Numbers above the sequences correspond to S. epidermidis MDD.  Red stars 
below the sequences correspond to invariant amino acid side chains involved in DPGP and FMVAPP 
interaction, while the green star represents the single variable active site residue.      
 
Fig. S2.  Analytical size-exclusion chromatography of recombinant S. epidermidis MDD.  A, Purified 
MDD was injected onto a Tricorn 10/300 Superdex 200 (GE Bioscience) analytical size-exclusion 
chromatography column and its retention time was compared to a series of globular protein standards 
(BioRad).  B, Size-exclusion calibration curve for four globular protein standards.  The apparent 
molecular weight (M.W.) for MDD was estimated from observed elution volume (E.V.) using the 
equation: M.W.=29,649e
-0.431xE.V.
.  For an elution volume of 14.05 ml, this yields an apparent molecular 




Tables S1 and S2.  Intermolecular contacts between S. epidermidis MDD and the inhibitors DPGP 
and FMVAPP.  Distances for polar contacts between selected atoms of the MDD protein and inhibitors 
DPGP (Table S1) and FMVAPP (Table S2).  In Table S2, distances are shown for both the wild-type and 
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Supplemental Tables 1 & 2
Enzyme Distance (Å) Inhibitor
Amino Acid Atom DPGP Atom Group
Tyr18 OH 2.7 OAF β-phosphoryl
Lys21 NZ 2.6 OAC β-phosphoryl
Ser107 OG 2.9 OAD α-phosphoryl
Ser139 OG 3.1 OAH α-phosphoryl
Ser139 OG 3.1 OAG β-phosphoryl
Gly140 N 2.9 OAF β-phosphoryl
Ser141 OG 2.6 OAH α-phosphoryl
Ser141 N 3.1 OAD α-phosphoryl
Arg144 NH2 2.8 O Carboxylate
Arg144 NH1 3.1 O Carboxylate
Ser192 OG 3.0 OAM α-phosphoryl
Ser192 OG 3.2 OAB C2-hydroxyl
Arg193 NH2 2.9 OAG β-phosphoryl
Arg193 NE 2.8 OAC β-phosphoryl
Enzyme Distance (Å) Inhibitor
Amino Acid Atom FMVAPP Ser192→Ala Atom Group
Tyr18 OH 2.8 2.7 OAF β-phosphoryl
Tyr18 N 2.9 2.8 OAD Carboxylate
Lys21 NZ 2.8 2.7 OAB β-phosphoryl
Ser139 OG 3.2 3.0 OAC α-phosphoryl
Ser139 OG 2.6 2.7 OAG β-phosphoryl
Gly140 N 2.8 2.8 OAF β-phosphoryl
Ser141 OG 2.8 2.7 OAC α-phosphoryl
Ser141 N 3.0 3.0 OAC α-phosphoryl
Arg144 NH2 2.9 3.0 OAA Carboxylate
Arg144 NH1 3.1 3.1 OAD Carboxylate
Ser192 OG 2.8 N/A OAH α-phosphoryl
Arg193 NH2 3.1 3.0 OAG β-phosphoryl
Arg193 NE 2.7 2.7 OAB β-phosphoryl
Asp283 OD 3.4 3.6 OAE C3-hydroxyl
Ala284 N 3.1 3.1 FAI Fluoromethyl
Table S1.  MDD + DPGP Contacts Table S2.  MDD + FMVAPP Contacts 
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